The tariff threat come just a few days after the White House sent letters to major drugmakers demanding slashed prices for US ...

Investing in clinical-stage biotechnology always carries significant risks, and aTyr is no exception. The company reported a ...

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Bristol-Myers Squibb recently saw a 6.39% drop in its stock value, with weak momentum and bearish signals from technical ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for lymphoma and death in a study.

In 2017, Megan Wanzo was pursuing health care ethics, uncertain but hopeful that she was on the right path, when she attended ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa ...

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before the bell.